Analysts await Valeant Pharmaceuticals Intl Inc (TSE:VRX) to reports
earnings on February, 22. They expect $3.54 EPS, up 7.27 % or $0.24 from
last year’s $3.3 per share. T_VRX’s profit will be $1.21 billion for
8.26 P/E if the $3.54 EPS becomes reality. After $3.62 actual EPS
reported by Valeant Pharmaceuticals Intl Inc for the previous quarter,
Wall Street now forecasts -2.21 % negative EPS growth.
The stock
decreased 9.63% or $12.47 on February 19, hitting $117. About 814,078
shares traded hands or 47.10% up from the average. Valeant
Pharmaceuticals Intl Inc (TSE:VRX) has declined 61.61% since July 15,
2015 and is downtrending. It has underperformed by 51.89% the
S&P500.
Valeant Pharmaceuticals International, Inc. is a specialty
pharmaceutical and medical device company. The company has a market cap
of $39.87 billion. The Firm is engaged in developing, manufacturing, and
marketing a range of branded, generic and branded generic
pharmaceuticals, over-the-counter products, and medical devices (contact
lenses, intraocular lenses, ophthalmic surgical equipment, and
aesthetics devices), which are marketed directly or indirectly in over
100 countries. It has 48.25 P/E ratio. The Firm operates through two
divisions: developed markets and emerging markets.
By: Maryann Pearce (Earnings Announcements).
Review: Emerging Market Formulations &
Research Unit, Flagship Records.
For The #FacebookTeam
